IP Library Granted Patent US 9,321,743
Granted Patent B2
US 9,321,743 · App. 13/898,225 · Granted Apr 26, 2016

Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,321,743
App. No.
13/898,225
Granted
Apr 26, 2016
Kind
B2
Abstract

Compounds and pharmaceutical compositions are contemplated that inhibit N-acyl-ethanolamine-hydrolyzing acid amidase (NAAA) to so increase the concentration of the substrate of NAAA, palmitoylethanolamide (PEA). NAAA inhibition is contemplated to be effective to alleviate conditions associated with a reduced concentration of PEA. Among other uses, various NAAA inhibitors are especially contemplated as therapeutic agents in the treatment of inflammatory diseases.

Claims (32)

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to the following formula effective to inhibit N-acyl-ethanolamine-hydrolyzing acid amidase

wherein

A is O or S; B is O, S, or NR a ; R 1 and R 2 are independently H, halogen, or optionally substituted lower alkyl; X is O, S, C(O), NR b , CHR b or null; Y is C(O), C(S), or CHR c ; Z is O, S, NR d , or CHR d ; V is methyl, ethyl, n-propyl, n-butyl, t-butyl, i-butyl, 2-methylpropyl, cyclopropylmethyl, i-amyl, n-amyl, hexyl or optionally substituted lower alkenyl; wherein W is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloheteroalkyl, or C(R 3 R 4 R 5 );

with the proviso that when V is methyl and W is phenyl, then Z is CHR d or NR d ;

wherein R a , R b , R c and R d are independently H, optionally substituted lower alkyl, or optionally substituted lower thioalkyl; and

wherein R 3 , R 4 , and R 5 are independently H or lower alkyl.

2. The pharmaceutical composition of claim 1 wherein A and B are O.

3. The pharmaceutical composition of claim 1 wherein X is NR b and Y is C(O) or C(S).

4. The pharmaceutical composition of claim 1 wherein Z is O or CHR d , V is lower alkyl, and wherein W is aryl or lower alkyl.

5. The pharmaceutical composition of claim 1 wherein, R 1 is H and R 2 is lower alkyl.

6. The pharmaceutical composition of claim 1 wherein A is O, B is O or NR a , X is NR b and Y is C(O) or C(S).

7. The pharmaceutical composition of claim 6 wherein W is aryl or lower alkyl.

8. The pharmaceutical composition of claim 1 , wherein V is n-amyl.

9. The pharmaceutical composition of claim 3 wherein Z is O or CHR d , V is lower alkyl, and wherein W is aryl or lower alkyl.

10. The pharmaceutical composition of claim 3 , wherein R 1 is H and R 2 is lower alkyl.

11. A compound having the structure of the following formula

wherein

A is O or S; B is O, S, or NR a ; R 1 and R 2 are independently H, halogen, or optionally substituted lower alkyl; X is O, S, C(O), NR b , CHR b or null; Y is C(O), C(S), or CHR c ; Z is O, S, NR d , or CHR d ; V is methyl, ethyl, n-propyl, n-butyl, t-butyl, i-butyl, 2-methylpropyl, cyclopropylmethyl, i-amyl, n-amyl, hexyl or optionally substituted lower alkenyl; wherein W is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloheteroalkyl, or C(R 3 R 4 R 5 );

with the proviso that when V is methyl and W is phenyl, then Z is CHR d or NR d ;

wherein R a , R b , R c , and R d are independently H, optionally substituted lower alkyl, or optionally substituted lower thioalkyl; and

wherein R 3 , R 4 , and R 5 are independently H or lower alkyl.

12. The compound of claim 11 wherein A and B are O.

13. The compound of claim 11 wherein X is NR b and Y is C(O) or C(S).

14. The compound of claim 11 wherein Z is O or CHR d .

15. The compound of claim 11 wherein, R 1 is H and R 2 is lower alkyl.

16. The compound of claim 11 wherein A is O, B is O or NR a , X is NR b and Y is C(O) or C(S).

17. The compound of claim 11 wherein W is aryl or lower alkyl.

18. The compound of claim 11 , wherein W is phenyl substituted with hydroxyl, thiol, alkylthiol, halogen, alkoxy, amino, amido, nitro, carboxyl, cycloalkyl, heterocycle, cycloheteroalkyl, acyl, carboxyl, aryl, aryloxy, heteroaryl, arylalkyl, heteroarylalkyl, alkyl, alkenyl, alknyl or cyano.

19. The compound of claim 18 , wherein W is biphenyl.

20. The compound of claim 11 , wherein W is phenyl.

21. The compound of claim 11 , wherein V is n-amyl.

22. The compound of claim 16 , wherein Z is O or CHR d and wherein W is aryl or lower alkyl.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2013
From: PIOMELLI, DANIELE
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 030941/0258 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2013
From: MOR, MARCO
To: UNIVERSITA DEGLI STUDI DI PARMA
Reel/Frame 030941/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2013
From: TARZIA, GIORGIO; DURANTI, ANDREA; TONTINI, ANDREA
To: UNIVERSITA DEGLI STUDI DI URBINO "CARLO BO"
Reel/Frame 030943/0767 →